Evidence map›Paper›PMID 41465734›Full record

ArticleLife (Basel, Switzerland)2025

Improvement of Cystic Fibrosis-Associated Liver Disease in Adults on Long-Term Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.

Sofia Manioudaki, Larisa Vasilieva, Eleni Geladari, Iliana Mani, Zoe Athanassa, Ioannis Elefsiniotis, Emilia Hadziyannis, Vasilios Sevastianos, Aikaterini Oikonomou, Andreas Theophilou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cystic Fibrosis: A Disease with a New Face.Life (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sofia ManioudakiIntensive Care Unit, Sismanogleio General Hospital, 15126 Athens, Greece.
Larisa VasilievaDepartment of Gastroenterology, Alexandra General Hospital, 11528 Athens, Greece.ORCID 0000-0001-7926-3062
Eleni Geladari3rd Department of Internal Medicine and Liver Outpatient Clinic, Evangelismos General Hospital, 10676 Athens, Greece.
Iliana Mani2nd Department of Internal Medicine and Research Laboratory, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.
Zoe AthanassaIntensive Care Unit, Sismanogleio General Hospital, 15126 Athens, Greece.
Ioannis ElefsiniotisHepatogastroenterology Unit, Academic Department of Internal Medicine, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, 14564 Athens, Greece.
Emilia Hadziyannis2nd Department of Internal Medicine and Research Laboratory, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.
Vasilios Sevastianos3rd Department of Internal Medicine and Liver Outpatient Clinic, Evangelismos General Hospital, 10676 Athens, Greece.ORCID 0000-0001-6725-3510
Aikaterini Oikonomou3rd Department of Internal Medicine, Sotiria Thoracic Diseases Hospital, 11527 Athens, Greece.ORCID 0009-0004-4702-8411
Andreas TheophilouMedical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0008-6145-1661
Filia DiamanteaAdult Cystic Fibrosis Unit, Sismanoglio Hospital, 15126 Athens, Greece.
Alexandra Alexopoulou2nd Department of Internal Medicine and Research Laboratory, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.ORCID 0000-0003-1991-7436

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators have been reported to improve lung function and reduce CF exacerbations. We aimed to investigate the efficacy of CFTR-modulators in CF-associated liver disease (CFLD) during long-term treatment. Longitudinal data were collected from genetically confirmed adult CF patients receiving CFTR-modulators. CFLD was diagnosed using conventional criteria combined with liver stiffness measurement (LSM). A total of 57 patients [56.1% male; median age at baseline (T0), 26 years (interquartile range [IQR], 23-35)] were included. Patients received lumacaftor/ivacaftor and/or elexacaftor/tezacaftor/ivacaftor for a median of 43 months (range, 15-123) until last assessment (T2). The prevalence of CFLD decreased from 15 (26.3%) at T0 to 8 (14.0%) at T2 (

Indexed as

adultsCFTR modulatorscystic fibrosiscystic fibrosis-related liver diseaseelexacaftor/tezacaftor/ivacaftorliver stiffnesslumacaftor/ivacaftor

Identifiers

PMID41465734
PMCPMC12734353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.